Med Polonia Sp. z o.o.
- Address
- lock Available on a paid plan
Med Polonia Sp. z o.o. - Advanced Oncology & Immunology Research Center
Med Polonia Sp. z o.o. is a specialized clinical research center with extensive expertise in advanced oncology trials and immunological disorders. The center has established itself as a key contributor to groundbreaking research in targeted cancer therapies and immunotherapy combinations, with particular emphasis on lung cancer treatment pathways and novel therapeutic approaches across multiple tumor types.
- Non-Small Cell Lung Cancer (NSCLC) - including advanced, metastatic, and mutation-specific subtypes such as KRAS G12C and EGFR Exon 20 insertion mutations
- Small Cell Lung Cancer (SCLC) - extensive-stage disease with combination immunotherapy and chemotherapy protocols
- Multiple Sclerosis and autoimmune conditions - including relapsing-remitting MS, Sjögren's syndrome, and rheumatoid arthritis
- Metastatic Breast Cancer and Renal Cell Carcinoma - novel antibody-drug conjugates and combination therapies
The center demonstrates significant experience with pembrolizumab-based combinations, biosimilar comparability studies, and Phase 1-3 clinical trials evaluating both monotherapies and complex combination regimens. Med Polonia's research portfolio extends beyond oncology to include cardiovascular conditions such as atrial fibrillation and specialized wound healing studies for diabetic foot ulcers, showcasing their versatility in conducting diverse therapeutic area investigations with rigorous scientific methodology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 14 therapeutic areas and 15 of 156 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 153 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 30 by active trials.
lock +29 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB7trials
lock +26 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Med Polonia Sp. z o.o.
lock Showing 1 of 111 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis | Biogen Idec Research Limited | Phase II | Not Recruiting | Oct 2023 | Feb 2026 |
IMP list
lock Showing 1 of 156 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 27 | Unknown | 2018-07-20 | 2026-03-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.